bpc-157 clinical trials human evidence review safety regulatory status Umbrella Labs BPC157 Liquid Spray Peptide Where the current evidence on
Description
doi:10.1016/j.brainres.2004.08.065
The activation of SIRT1 through increased NAD+ availability improves how cells respond to insulin, facilitating better glucose uptake and utilization
Gastrointestinal Therapeutics Given BPC-157's origin from gastric juice and extensive preclinical evidence for gastrointestinal protection, digestive system applications warrant clinical investigation
10.1038/s41598-023-34916-z 117 RobertsT
